Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Universitatsklinikum Hamburg-Eppendorf manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 1 pending office action. This action is assigned to 1 distinct examiner and 1 distinct art unit. This configuration suggests that the company's current patent prosecution is focused within the identified technical and administrative designations.
PENNINGTON, KATIE LEIGH is the busiest examiner for the portfolio, with 1 pending office action. For the practitioner, this means that the 1 pending office action is subject to the specific examination style and history of PENNINGTON, KATIE LEIGH. Because the portfolio involves 1 distinct examiner, the company can focus its resources on the preferences of this individual rather than managing diverse perspectives.
The involvement of 1 distinct art unit suggests that the subject matter of the pending office action is confined to a specific technical niche within the Biotechnology & Pharmaceuticals technology area. This concentration simplifies the management of the portfolio, as the prosecution is not divided across art units. The current data reflects a targeted approach to patent acquisition, with all active prosecution consolidated under these specific designations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PENNINGTON, KATIE LEIGH | 1 | 31.8% | +58.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17052484 | Fusion Proteins Comprising a Cell Surface Marker Specific VHH | PENNINGTON, KATIE LEIGH | 15d |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17052484 | Fusion Proteins Comprising a Cell Surface Marker Specific VHH | PENNINGTON, KATIE LEIGH | 1634 | §103 | Non-Final OA | 15d | Pending | Nov 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversitatsklinikum Hamburg-Eppendorf has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katie Leigh Pennington has the most, with 1 of Universitatsklinikum Hamburg-Eppendorf's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.